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Diagnosing chronic pulmonary aspergillosis (CPA) is complicated, and limited data 
regarding the detection of galactomannan (GM) in clinical specimens are available. The 
purpose of this study was to evaluate the detection of GM in bronchoalveolar lavage 
fluid (BALF) and serum and to assess its utility for diagnosing CPA. We retrospectively 
reviewed the diagnostic and clinical characteristics of 144 patients with and without 
CPA whose BAL and serum were examined for the presence of GM in Nagasaki 
University Hospital, Japan. The Platelia Aspergillus enzyme immunoassay (PA EIA) 
was performed according to the manufacturer’s instructions. Of the 144 patients, 18 had 
CPA and 126 patients did not have CPA. The mean values of BALF GM antigen were 
4.535 (range, 0.062–14.120) and 0.430 (range, 0.062–9.285) in CPA and non-CPA 
patients, respectively. The mean values of serum GM antigen were 1.557 (range, 
0.232–5.397) and 0.864 (range, 0.028–8.956) in CPA and non-CPA patients, 
respectively. PA EIA with BALF is superior to PA EIA with serum, according to 
receiver operating characteristics analysis; the optimal cut-off values for BALF and 
serum were 0.4 and 0.7, respectively. The sensitivity and specificity of PA EIA with 
BALF at a cut-off of 0.4 were 77.2% and 77.0%, respectively. The sensitivity and 
specificity of PA EIA with serum at a cut-off of 0.7 were 66.7% and 63.5%, respectively. 
GM testing using BALF showed reasonable sensitivity and specificity as compared to 





bronchoalveolar lavage, galactomannan, chronic, pulmonary, aspergillosis 
INTRODUCTION 
 Chronic forms of pulmonary aspergillosis (CPA) are known as a slowly progressing 
inflammatory pulmonary syndrome caused by Aspergillus [1, 2]. These chronic forms 
include semi-invasive aspergillosis [3], chronic necrotizing pulmonary aspergillosis 
(CNPA) [4], chronic cavitary pulmonary aspergillosis (CCPA), chronic fibrosing 
pulmonary aspergillosis (CFPA), and simple and complex aspergilloma [5]. Hope et al. 
indicated [2] that apparently distinct entities do not exist for these subtypes, and they are 
usually overlapped. The common characteristics of these forms are as follows: (1) 
underlying pulmonary disorders (e.g., tuberculosis sequelae, bronchiectasis, chronic 
obstructive pulmonary disease, cystic lesions, and pulmonary fibrosis); (2) low-grade 
immunosuppression (e.g., low-dose steroid administration, diabetes, collagen diseases, 
renal disorders, or alcohol consumption) that is related to reduced host immunity; and 
(3) less severe findings than those of angioinvasion in histopathology [1, 5, 6]. 
Diagnosing CPA is problematic, which causes difficulty in establishing clear 
definitions of the previously stated subtypes of CPA. There are no reliable diagnostic 
methods for CPA, and the presence of underlying pulmonary diseases may make the 
problem worse, because these underlying diseases allow other microorganisms to cause 
co-infection with Aspergillus. Only Aspergillus antibody testing with the Aspergillus 
immunodiffusion system is useful, as reported by several previous studies [2, 5, 7, 8]. 
Aspergillus galactomannan (GM) is a polysaccharide component of the fungal cell wall 
that is released during tissue invasion by Aspergillus hyphae. A commercially available 
Platelia Aspergillus enzyme-linked immunosorbent assay (PA EIA; Bio-Rad 
Laboratories, Redmond, WA) detects the GM of most Aspergillus species. The overall 
sensitivity of PA EIA with serum is approximately 61–71%, with a specificity of 
89–93% for invasive aspergillosis [9]. However, a fairly low positive rate was obtained 
among CPA patients in limited studies [7, 8, 10]; therefore, this method is currently not 
considered useful for CPA diagnosis. 
Bronchoscopy with bronchoalveolar lavage (BAL) is an important tool for 
diagnosing pulmonary infections including fungal infection. The use of testing BAL 
fluid (BALF) for diagnosing invasive pulmonary aspergillosis (IPA) of various 
backgrounds has been reported previously [11-18]. Moreover, BALF testing 
compensates for the moderate sensitivity and relatively low positive predictive value 
(PPV) of serum GM testing.  
To date, very few studies have been performed on PA EIA with BALF in CPA patients. 
The objective of this study was to assess the use of the PA EIA with BALF for the 
diagnosis of CPA. 
MATERIALS AND METHODS 
Study design, BAL procedure, and GM measurement 
This retrospective study was conducted between May 1, 2005 and March 31, 2009. All 
adult inpatients (age, ≥15 years) in the respiratory ward who had undergone BAL for the 
diagnosis of pulmonary infectious diseases and PA EIA with both BALF and serum at 
the Second Department of Internal Medicine, Nagasaki University Hospital were 
eligible for inclusion in this study.  
Approximately 350–500 patients, including 150–200 new patients, are admitted to this 
respiratory department ward per year, and the most commonly observed lung disease in 
this department is lung cancer. BAL was performed according to the methods of 
individual pneumologists. The bronchus of the lobe in which consolidation or a newly 
appeared shadow was imaged by chest radiography or computed tomography (CT), and 
20–50 ml of 0.9% sterile prewarmed saline solution was instilled with a syringe through 
the working channel of the bronchoscope. The total volume of saline solution instilled 
into the lungs was typically 150 ml, and 10–100 ml of BALF was recovered. BALF and 
serum samples were directly used for evaluating GM by using the PA EIA according to 
the manufacturer’s instructions. Each BALF sample was centrifuged for 10 min at 3000 
rpm, and a total of 300 μl of supernatant was used for the measurement. Patients with a 
provisional diagnosis of lower respiratory infection were assessed by each study 
investigator to confirm the diagnosis. Clinical information such as age, sex, existing 
underlying diseases, complications, prior usage of drugs (such as antibiotics including 
antifungal drugs, anti-cancer drugs, immunosuppressive agents, biological agents, and 
steroids), and presence of cavitary lesions and/or fungus balls on chest X-ray films, 
including CT, was recorded retrospectively. 
The diagnostic criteria of Hope et al. for all subtypes of CPA, including CNPA, CCPA, 
CFPA, and simple aspergilloma, were used in this study [2]. Proposed enrollment 
criteria for prospective clinical studies of CPA by Denning were also used for this study 
with minor modifications [5]. Patients with CPA had to fulfill the following conditions: 
(1) presence of at least one of the symptoms from a complex of fever, weight loss, 
sputum, cough, hemoptysis, fatigue, and shortness of breath; (2) new infiltrates, cavity 
formation, or expansion of pre-existing cavities with or without pericavitary infiltrates 
and adjacent pleural thickening; (3) either a positive result in the Aspergillus 
immunodiffusion system (Microgen Bioproducts, Ltd., Camberley, United Kingdom) 
for anti-Aspergillus antibody in serum or for the isolation of Aspergillus spp. from 
BALF; (4) positive findings for at least one of the inflammation markers such as white 
blood cell counts, C-reactive protein levels, and erythrocyte sedimentation rate; and (5) 
lack of improvement of symptoms or signs after at least 3 days of broad-spectrum 
antibiotics administration. (1,3)-β-D-glucan test (cut-off = 20 pg/ml for the Fungitec G 
Test, Seikagaku Corporation, Tokyo, Japan) by using serum was also performed to 
obtain supportive data.  
This study was approved by the ethical committee of Nagasaki University Hospital, 




The sensitivity, specificity, PPV, and negative predictive value (NPV) were calculated 
for PA EIA with serum and BALF. The Mann-Whitney U test was used to compare 
paired data (means of GM testing with serum and BALF between CPA and non-CPA 
groups). False-positive fractions were compared using univariate analysis, and the 
chi-square test was used for qualitative variables. Correlation coefficients between 
variables were calculated. Multivariate logistic regression analysis was performed using 
the variables that were selected from univariate analysis (P < 0.1) and correlation 
analysis (|r| > 0.224). The optimal threshold level for PA EIA with serum and BALF was 
determined by receiver operating characteristics (ROC) analysis. This analysis was 
performed by SPSS ver. 16, software. A P-value < 0.05 was considered statistically 
significant. 
RESULTS 
Profile of recruited patients 
We studied 18 CPA patients and 126 non-CPA patients (total, 144 patients). Table 1 
shows the mean age, sex, and underlying diseases and conditions of the evaluated 
patients. The mean age of all patients was relatively high at 64.8 years, and 61.8% of 
these patients were men. Patients with bronchiectasis were the most dominant 
population, followed by patients with interstitial pneumonia, chronic obstructive 
pulmonary disease (COPD), and lung cancer. The mean age of the 18 CPA patients was 
68.6 years, and 88.9% of these patients were men. COPD, bronchiectasis, and 
tuberculosis sequelae were predominant as underlying diseases in CPA patients. Other 
underlying diseases and conditions in non-CPA patients are also listed in Table 1. 
 
Characteristics of CPA patients 
The characteristics of CPA patients are indicated in Table 2. All the 18 patients met 
the disease criteria for CPA for this study. Eleven (61.1%) patients were positive for 
Aspergillus antibody titer, and 7 (38.9%) were positive for serum β-D-glucan. 
Aspergillus was isolated from the BALF of all CPA patients excluding 1 patient (case no. 
8), and the most frequent isolate from BALF was A. fumigatus (11 patients), followed 
by A. niger (2 patients), A. terreus (2 patients), A. flavus (1 patient), A. nidulans (1 
patient), and unidentified Aspergillus spp (1 patient). Radiological analysis showed 
cavitary lesions with fungus balls in 12 patients (66.7%). Prior usage of antibiotics was 
recognized in 1 patient (case no. 8), and beta-lactams without beta-lactamase inhibitors 
were used by this patient. Antifungal drugs were not used by any CPA patient before PA 
EIA was performed.  
 
Comparison of GM antigen titers between patients with and without CPA 
The mean values of GM antigen in BALF were 4.535 (range, 0.062–14.120) in CPA 
patients and 0.430 (range, 0.062–9.285) in non-CPA patients. The mean values of GM 
antigen in serum were 1.557 (range, 0.232–5.397) in CPA patients and 0.864 (range, 
0.028–8.956) in non-CPA patients. The mean GM values of PA EIA with both BALF 
and serum were statistically higher in CPA patients than in non-CPA patients (P < 0.01 
for both serum and BALF). 
The ROC curve in the generalized estimation equation model for PA EIA is presented 
in Figure 1. The area under the curve (AUC) was larger for PA EIA with BALF (0.775) 
than for PA EIA with serum (0.711). The optimal cut-offs of PA EIA calculated from the 
ROC curve were 0.4 and 0.7 for BALF and serum, respectively. Table 3 shows the 
sensitivity, specificity, PPV, and NPV of PA EIA with BALF and serum for diagnosing 
CPA with a cut-off established by ROC analysis (0.4 for BALF and 0.7 for serum). Both 
the sensitivity and specificity of PA EIA were superior for BALF than for serum, which 
was also confirmed by the larger AUC in the ROC analysis. 
 
Factors associated with the false positivity of GM tests in non-CPA patients 
 Of the 126 non-CPA patients studied, 29 (23.0%) had a positive GM titer in BALF 
with a cut-off of 0.4. Age, sex, and various conditions such as underlying diseases, drug 
usage, radiological findings, and fungal isolates from BALF were evaluated to detect 
the factors associated with false positivity of PA EIA with BALF. Table 4 shows the 
results of univariate analysis. The presence of bulla in the lungs according to 
radiological findings and the presence of Penicillium spp. in respiratory specimens 
statistically influenced the false-positive results of PA EIA with BALF. Multivariate 
analysis also identified these 2 factors as being significantly associated with false 
positivity of PA EIA with BALF. The P values for the presence of bulla and Penicillium 
spp. were 0.03 and 0.04, respectively.
DISCUSSION 
CPA usually occurs in middle-aged to elderly patients with underlying chronic 
pulmonary diseases. It slowly progresses over months and even years, causing lung 
destruction as evidenced by progressive cavitation, fibrosis, and pleural thickening [10]. 
The 5-year survival rate of CPA patients in Korea is reported to be approximately 50%; 
however, epidemiological studies are limited [19]. Pre-existing or residual cavities after 
mycobacterial infection are common dwelling sites of Aspergillus. Other pulmonary 
diseases such as emphysematous bullae, COPD, and bronchiectasis that result in 
cavitation can cause CPA [2, 20]. Although early diagnosis of CPA is important, the 
complexity of the background of underlying pulmonary diseases may preclude a rapid 
and precise diagnosis of CPA. Although pathological examination is required for a 
definitive diagnosis of CPA, acquiring tissues by using invasive procedures may be 
difficult because of the underlying pulmonary diseases mentioned above. In our study, 
diagnosis of definite CPA cases by pathological examination was not made in all CPA 
cases. However, in practice most CPA patients are diagnosed using clinical, radiological, 
and mycological factors except pathological findings in practice. 
PA EIA has been approved for the diagnosis of aspergillosis, especially IPA, with a high 
sensitivity and specificity at a cut-off of 0.5 by using serum. Our previous clinical study 
showed a low positive rate (48.9% at a cut-off of 0.5) of detecting CPA by using serum. 
Similarly, a study in Japan reported that PA EIA positivity was only 50.0% at a cut-off 
of 0.5 [8]. Thus, PA EIA is not suitable for diagnosing CPA by using serum as a sample 
[7]. Although the use of BALF instead of serum for the diagnosis of IPA of various 
backgrounds has been reported previously [11-18], the potential use of this test in CPA 
patients is very limited. The primary objective in this study was to compare the utility of 
PA EIA with BALF and PA EIA with serum. 
The features of CPA patients in this study were as follows: (1) various underlying 
conditions such as previous tuberculosis infection, COPD, and bronchiectasis; (2) 
middle-aged to elderly patients; (3) primarily male patients; and (4) a relatively high 
positive rate for the Aspergillus antibody test (61.1%). These features matched the 
findings reported in previous studies, including our recent clinical study [7, 19, 20]. 
Although beta-lactams with beta-lactamase inhibitors influence the result of PA EIA 
with serum [21, 22], no such drugs were used in this study. Furthermore, antifungal 
drugs were not administered to any patient until at least 4 weeks prior to timing of PA 
EIA with BALF and serum. Thus, influence of the prior treatment of antibiotics and 
antifungals on the results of PA EIA can be ignored in this study.  
A comparison of actual GM antigen titers between patients with and without CPA 
indicated that GM titer in the BALF and serum of CPA patients was statistically higher 
than that in the BALF and serum of non-CPA patients. Our attempt to estimate optimal 
cut-off values for PA EIA with BALF and serum from ROC curves indicated that the 
optimal cut-off values for BALF and serum were 0.4 and 0.7, respectively. The 
sensitivity and specificity of PA EIA by using the new cut-offs showed that BALF is 
superior to serum as the target sample for diagnosing CPA. However, no dramatic 
increase was observed in its utility for diagnosing CPA as compared to that reported in a 
similar study by Park et al. [23]. Park et al. reported that the sensitivity of PA EIA with 
BALF for a cut-off of 0.5 in 36 patients with single pulmonary cavity containing a 
fungus ball was 92% [23]. Hence, our result in 18 CPA patients showed a lower 
sensitivity of 72.2% at a cut-off of 0.4 (61.1% at a cut-off of 0.5). The major difference 
in the present study and the study by Park et al. was the patient population (subtypes of 
CPA). In our study, almost all patients had multiple cavities with or without fungus 
balls; moreover, the complexity of lesions in the lungs due to underlying diseases may 
have influenced the results of our study. Moreover, because our study was retrospective, 
the ability to estimate the power of the diagnostic tool was limited. 
Because it is also important to assess the false-positive rate for diagnosing CPA by 
using the PA EIA with BALF, we examined the factors associated with false positivity 
in non-CPA patients. Our data indicated that presence of bulla on a chest radiograph and 
detection of Penicillium spp. in BALF were significantly associated with false-positive 
results of PA EIA with BALF. Both univariate and multivariate analyses confirmed the 
significance of these factors. Bulla lesions can be colonized by Aspergillus, and PA EIA 
can detect GM from colonized Aspergillus. Moreover, because PA EIA showed 
cross-reactivity with some Penicillium spp. in an in vitro study [24], it is possible to 
detect Penicillium spp. antigens in BALF by using this method. To the best of our 
knowledge, this is the first study to identify a relationship between the presence of 
Penicillium spp. in BALF and false positivity of PA EIA with BALF. There were only 
four cases of which Aspergillus spp. (A. niger, A. versicolor, and A. flavus) were 
isolated from BALF by culturing BALF from 126 non-CPA patients; of these, 2 patients 
were indicated positive by using PA EIA (data not shown). Because Aspergillus is a 
ubiquitous fungus and may exist in any environment, it is possible that it colonizes the 
respiratory tract or contaminates the samples during handling. Therefore, careful 
assessment of the results of PA EIA with BALF is still required. Because some studies, 
including our previous clinical study (88.6% positivity), have reported the use of the 
serum Aspergillus precipitins test for detecting antibodies to Aspergillus for CPA 
patients [1, 7, 8, 19], a combined use of an antibody test and PA EIA with BALF but not 
serum may prove potentially useful.  
In conclusion, this is the first report to address the use of PA EIA with BALF for the 
diagnosis of CPA. This test has reasonable sensitivity and specificity at a cut-off of 0.4 
as compared to the use of serum. Diagnosis of CPA requires synthetic assessment of 
clinical, radiological, mycological, and serological factors, and it is apparent that no 
single serological test is universally applicable. However, PA EIA with BALF may have 
a potential use for the diagnosis of CPA. Prospective and large-scaled studies are still 
warranted, and newer biomarkers that reflect a more precise state of CPA are also 
expected. 
Figure legend 
Figure 1. Receiver operating characteristic curve for the galactomannan test with serum 
and bronchoalveolar lavage fluid (BALF).The area under the curve was larger for the 
Platelia Aspergillus enzyme-linked immunosorbent assay with BALF (0.775) than that 
for the assay with serum (0.711). 
Table 1. Characteristice of patients
Total (144 cases) CPA cases (18 cases) non-CPA cases (126 cases)
Age 64.8 (range: 23-84) 68.6 (range: 53-83) 64.2 (range: 23-84)
Sex, # of male 89 (61.8) 16 (88.9) 73 (57.9)
underlying diseases and conditions
　tuberculosis sequelae 15 (10.4) 8 (44.4) 7 (5.6)
　COPD 29 (20.1) 11 (61.1) 18 (14.3)
　non-mycobacterium infection 18 (12.5) 4 (22.2) 14 (11.1)
　bronchiectasis 39 (27.1) 11 (61.1) 28 (22.2)
　interstitial pneumonia 32 (22.2) 1 (5.6) 31 (24.6)
　lung cancer 26 (18.1) 1 (5.6) 25 (19.8)
　abnormal findings in chest X-ray 18 (14.3)
   films without symptoms
　organizing pneumonia 11 (8.7)
　pulmonary cryptococcosis 8 (6.3)
　pneumonia 8 (5.6) 1 (5.6) 7 (5.6)




　hypersensitivity pneumonitis 2 (1.6)
　drug induced pneumonitis 2 (1.6)
　others 8 (6.3)
COPD, chronic obstructive pulmonary diseases; NTM. Non-tuberculosis mycobacterium; ABPM, allergic bronchopulmonary mycoses
CPA, chronic pulmonary aspergillosis  
Table 2. Characteristice of patients with chronic pulmonary aspegillosis
Aspergillus
antibody
BALF serum  (pg/ml) cavitary lesion fungus ball beta-lactams antifungals
1 73 M 0.062 0.718 - 4.2 A. fumigatus + + - -
2 81 M 0.111 2.113 - 4.3 A. fumigatus + - - -
3 61 M 0.154 0.786 + 26.7 A. nidulans + + - -
4 76 M 0.209 3.032 - 7.4 A. niger - - - -
5 77 M 0.254 0.607 - 7.2 A. fumigatus + - - -
6 72 M 0.426 3.310 - 8.6 A. fumigatus + + - -
7 55 M 0.452 0.232 + 312.9 A. fumigatus + + - -
8 70 M 0.607 0.285 + 5.1 N.D. + + + -
9 75 M 0.736 1.302 + 17.3 A. fumigatus + + - -
10 60 F 1.112 2.083 + 8.4 A. niger - + - -
11 55 M 1.628 0.267 + 372.2 A. fumigatus + + - -
12 76 M 7.314 2.360 - 9.2 A. flavus + + - -
13 65 M 8.409 2.391 + 7.9 A. fumigatus   A. terreus + + - -
14 53 M 8.882 0.496 + 153.7 A. fumigatus + + - -
15 65 M 11.370 0.650 + 39.5 A. fumigatus + + - -
16 80 M 11.950 1.150 - 5.4 Aspergillus  spp. + - - -
17 57 F 13.837 5.397 + 92.3 A. fumigatus + + - -
18 83 M 14.120 0.852 + 28.3 A. terreus + - - -
N.D., not detected; +, positive; -, negative






Aspergillus  isolated from
BALF
predictive value of galactomannan antigen test





PPV, positive predictive value; NPV, negative predictive value
Table 3. Sensitivity, specificity, positive predictive value, and negative
number of positive in 
non-CPA cases
number of GM positive 
cases (%)
number of GM negative 
cases (%)
P
Age, >65 74 19 (25.7) 55 (74.3) 0.398
Sex, Male 73 15 (20.5) 58 (79.5) 0.440
tuberculosis sequelae 7 2 (28.6) 5 (71.4) 0.719
COPD 18 3 (16.7) 15 (83.3) 0.489
NTM infection 14 6 (42.9) 8 (57.1) 0.061
bronchiectasis 28 8 (28.6) 20 (71.4) 0.428
interstitial pneumonia 31 10 (32.2) 21 (67.8) 0.159
diabetes 26 5 (19.2) 21 (80.8) 0.607
steroid 34 8 (23.5) 26 (76.5) 0.934
immunosuppressive agents 13 5 (38.5) 8 (61.5) 0.162
neutropenia 5 2 (40.0) 3 (60.0) 0.357
anti-cancer drug 5 1 (20.0) 4 (80.0) 0.870
renal failure 7 1 (14.3) 6 (85.7) 0.572
biological agents 1 0 (0.0) 1 (100.0) 0.583
cavitary lesions 13 2 (15.4) 11 (84.6) 0.490
consolidation 47 12 (25.5) 35 (74.5) 0.605
bulla 22 9  (40.9) 13 (59.1) 0.032
Penicillium  spp. detection 12 6 (50.0) 6 (50.0) 0.020
COPD, chronic obstructive pulmonary disease; NTM, not-tuberculosis mycobacterium
immunosuppressive agent includes alkylating agents and methotrexate
Table 4. False-positive factors of galactomannan test using BALF in non-CPA cases

 
Figure 1. Receiver operating characteristic curve for the galactomannan test with serum and bronchoalveolar lavage fluid 
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